Posts

Market Analyst Warning- Don’t Fall for Anacor’s Toenail Fungus Drug Hype

Back in November, we wrote about Anacor’s new drug, Tavaborale. In an industry where treatments are marginally effective at best, Anacor promised slightly-better-than-mediocre results. If Penlac cured 0.5% of patients, then Tavaborale would cure 6% of patients. The problem with topical toenail fungus treatments is that they are unable to make it past the nail barrier to penetrate deep into the nail matrix. We have to wonder, though: are these treatments really good enough? Is it worth developing something that works on less than a tenth of the population? David Sobek, a market analyst over at The Street, says no.

tavaborale

Though Anacor’s stock is rising, analysts say Tavaborale is a bust.
Image Source: SEC.gov

Read more

Novexatin: Big Pharma Searches For a Quick Toenail Fungus Cure

Sun Pharma has carved a name for itself as India’s largest drug maker, with 11,200 employees at manufacturing centers around the world, $1.2 billion in annual sales, and a stock that surged 72% last year. In America, they manufacture and market more than 200 generic drugs for heart medications, diabetes drugs, and cancer treatments. They provide Active Pharmaceutical Ingredients such as warfarin, carbamazepine, etodolac, clorazepate, sex hormones, peptides, steroids, and controlled substances.  Now they have their sights set on a much smaller, but nevertheless irritating, medical issue: RECURRENT TOENAIL FUNGUS.

sun pharma

Image Source: LiveMint.com

Read more